摘要

At present, monitoring tumor response to therapy is a crucial issue in oncology. In daily clinical practice, tumormarkers tests and anatomical imaging modalities are the most used techniques, but they have significant limits. Positron emission tomography (PET) is a molecular and functionnal imaging technique and, is by this fact, considered as a method of choice for assessing tumor response with cytotoxic chemotherapies and even more with targeted therapies. Some limits of 18F-fluoro-deoxy-glucose (18F-FDG) PET are overcome by the current development of new radioactive tracers. For those reasons, PET appears to be the most encouraging technique to assess tumor response for the next decade.

  • 出版日期2013-9

全文